Metraipolis › archive › dc_b685e7d0722b

Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy — Europe PMC PMID:42034063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42034063
DOI
10.1016/j.immuni.2026.03.028
License (as archived)
solo-consultazione
Archived
2026-11-03T07:20:34.609Z
SHA-256 of the archived text
ee402a62acd377c0394bd4a256c12d68c0e9fd045bf494f9e1409eff1c985edb
Stable URL of this page
https://metraipolis.com/documento/dc_b685e7d0722b

How to cite

Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy — Europe PMC PMID:42034063 — Europe PMC (en), https://europepmc.org/article/MED/42034063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b685e7d0722b (Metraipolis archive dc_b685e7d0722b, sha256 ee402a62acd377c0394bd4a256c12d68c0e9fd045bf494f9e1409eff1c985edb)
BibTeX
@misc{dcb685e7d0722b,
  title = {Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy — Europe PMC PMID:42034063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42034063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b685e7d0722b; sha256 ee402a62acd377c0394bd4a256c12d68c0e9fd045bf494f9e1409eff1c985edb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42034063. Agents can read the archived copy with the MCP tool read_document.